Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study is to assess the efficacy and safety of a four-week treatment with intranasal
esketamine (56 mg) twice a week combined with opioid analgesic and adjuvant standard therapy
in the management of adult patients with severe and opioid refractory chronic cancer pain.